A phase I trial of VB-111, a tissue- and condition-specific dual action vascular disruptive and antiangiogenic agent, for treatment of patients with advanced metastatic cancer.
A. J. Brenner
Consultant or Advisory Role - VBL Therapeutics
Research Funding - VBL Therapeutics
Y. Cohen
Employment or Leadership Position - VBL Therapeutics
F. J. Giles
Research Funding - VBL Therapeutics
E. C. Borden
Consultant or Advisory Role - VBL Therapeutics (U)
Research Funding - VBL Therapeutics
E. Breitbart
Employment or Leadership Position - VBL Therapeutics
L. Bangio
Employment or Leadership Position - VBL Therapeutics
N. Sher
Employment or Leadership Position - VBL Therapeutics (U)
P. L. Triozzi
Research Funding - VBL Therapeutics